Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Acquired by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 1.2% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 611,749 shares of the biotechnology company's stock after purchasing an additional 6,992 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.64% of Sarepta Therapeutics worth $76,401,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Innealta Capital LLC purchased a new position in Sarepta Therapeutics during the second quarter valued at $31,000. New Covenant Trust Company N.A. bought a new position in shares of Sarepta Therapeutics in the first quarter worth about $32,000. Nkcfo LLC purchased a new position in shares of Sarepta Therapeutics during the 2nd quarter valued at about $43,000. Huntington National Bank grew its stake in shares of Sarepta Therapeutics by 150.9% during the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company's stock valued at $36,000 after acquiring an additional 175 shares during the period. Finally, Riggs Asset Managment Co. Inc. increased its holdings in Sarepta Therapeutics by 33.3% in the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company's stock worth $47,000 after acquiring an additional 75 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Stock Up 5.7 %

SRPT traded up $7.44 on Thursday, hitting $137.94. The company had a trading volume of 2,917,222 shares, compared to its average volume of 1,248,402. The stock has a market capitalization of $13.18 billion, a price-to-earnings ratio of 110.35 and a beta of 0.81. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The stock has a fifty day moving average price of $122.16 and a 200-day moving average price of $131.43. Sarepta Therapeutics, Inc. has a 12-month low of $78.67 and a 12-month high of $173.25.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. StockNews.com cut shares of Sarepta Therapeutics from a "buy" rating to a "hold" rating in a research note on Wednesday, November 20th. UBS Group increased their price target on Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a "buy" rating in a research note on Tuesday, September 17th. Guggenheim boosted their price objective on Sarepta Therapeutics from $148.00 to $150.00 and gave the company a "buy" rating in a research report on Thursday, November 7th. Citigroup cut their target price on Sarepta Therapeutics from $176.00 to $160.00 and set a "neutral" rating for the company in a research report on Thursday, August 8th. Finally, HC Wainwright initiated coverage on Sarepta Therapeutics in a research note on Monday. They set a "sell" rating and a $80.00 target price on the stock. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, twenty have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Sarepta Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $175.77.

Insider Transactions at Sarepta Therapeutics

In other news, CFO Ian Michael Estepan sold 5,985 shares of the firm's stock in a transaction on Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the sale, the chief financial officer now owns 33,946 shares of the company's stock, valued at $4,662,822.56. This trade represents a 14.99 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 7.70% of the company's stock.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.